AstraZeneca Enhances Clinical Research Capabilities in China with First Clinical Pharmacology Unit
News Sep 05, 2007
AstraZeneca has announced a strategic partnership with Peking University 3rd Hospital to open its first Clinical Pharmacology Unit (CPU) in China. The unit aims to enhance local clinical research capabilities and speed up access to new medicines to benefit Chinese patients.
Han Qide, academician and vice chairman of the Standing Committee of the National People’s Congress; Sang Guowei, President of China Pharmaceutical Association; Chen Zhongqiang, Dean of Peking University 3rd Hospital; and David Brennan, CEO of AstraZeneca, were present at the opening ceremony.
The CPU will focus on Phase I clinical research, including clinical pharmacology and safety evaluations - steps necessary for launching new medicines in China. Under the co-operative agreement, AstraZeneca will provide Peking University 3rd Hospital with personnel training, system audits and consulting services, and will also invest to upgrade facilities necessary for clinical research of medicines for infections, diabetes, and cardiovascular diseases.
The unit will accelerate access to new medicines from overseas and benefit Chinese patients in need. In addition, it is set to expand the capabilities of early phase clinical research for local clinical pharmacology organisations, and take China’s clinical research capabilities to a new level through further R&D cooperation and academic exchange with the local medical community.